Inherited Thrombophilic Disorders in Young Adults With Ischemic Stroke and Patent Foramen Ovale
Open Access
- 1 January 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 34 (1) , 28-33
- https://doi.org/10.1161/01.str.0000046457.54037.cc
Abstract
Background and Purpose— The pathogenic link between patent foramen ovale (PFO) and stroke remains unknown in most cases. We investigated the association between inherited thrombophilic disorders and PFO-related strokes in a series of young adults in the setting of a case-control study. Methods— We investigated 125 consecutive subjects (age, 34.7±7.3 years) with ischemic stroke and 149 age- and sex-matched control subjects. PFO was assessed in all patients with transcranial Doppler sonography with intravenous injection of agitated saline according to a standardized protocol. Genetic analyses for the factor V (FV) G1691A mutation, the prothrombin (PT) G20210A variant, and the TT 677 genotype of methylenetetrahydrofolate reductase ( MTHFR ) were performed in all subjects. Results— A pathogenic role of PFO was presumed in 36 patients (PFO+). Interatrial right-to-left shunt either was not detected or was considered unrelated to stroke occurrence in the remaining 89 patients (PFO−). The PT G20210A variant was more frequent in the PFO+ group compared with control subjects and the PFO− group (PFO+ versus control subjects, 11% versus 2%; 95% CI, 0.04 to 0.94; PFO+ versus PFO−, 11% versus 1.1%; 95% CI, 1.09 to 109; P =0.047). A similar distribution was observed for subjects carrying either the PT G20210A variant or the FV G1691A mutation (PFO+ versus control subjects, 19.4% versus 5.3%; 95% CI, 0.08 to 0.75; PFO+ versus PFO−, 19.4% versus 3.3%; 95% CI, 1.45 to 26.1; P =0.021). Combined thrombophilic defects were observed in 3 subjects of the PFO+ group, in 2 control subjects (8.3% versus 1.3%; 95% CI, 0.01 to 0.66; P =0.015), and in 0 subjects in the PFO− group. A trend toward a difference in the frequency of the FV G1691A mutation between PFO+ and control subjects was found after bivariate analysis (11% versus 3.3%; P =0.068) but not after multinomial logistic regression analysis. No significant association was found in the distribution of the TT MTHFR genotype in the 3 groups. Conclusions— In young adults, the PT G20210A variant and, to a lesser extent, the FV G1691A mutation may represent risk factors for PFO-related cerebral infarcts. A role of systemic thrombophilic disorders in the pathogenesis of this specific subtype of stroke may be hypothesized.Keywords
This publication has 30 references indexed in Scilit:
- Effect of Medical Treatment in Stroke Patients With Patent Foramen OvaleCirculation, 2002
- Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale, Atrial Septal Aneurysm, or BothNew England Journal of Medicine, 2001
- Secondary Prevention of Cerebral Ischemia in Patent Foramen OvaleSouthern Medical Journal, 2001
- Vascular-Bed–Specific Hemostasis and Hypercoagulable StatesNew England Journal of Medicine, 1999
- Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attackAmerican Heart Journal, 1995
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Validation of Transcranial Doppler Sonography in the Assessment of Patent Foramen OvaleCerebrovascular Diseases, 1995
- In Vitro Diagnosis of Fibrinolysis: Present Status and Desired ImprovementsAnnals of the New York Academy of Sciences, 1992
- PATENT FORAMEN OVALE IN YOUNG STROKE PATIENTSThe Lancet, 1988
- Prevalence of Patent Foramen Ovale in Patients with StrokeNew England Journal of Medicine, 1988